MetaCap

CAMP4 Therapeutics Corporation (CAMP)

NASDAQ: CAMPHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.79-0.21 (-5.25%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CAMP stock chart

Technical analysis

Key statistics

All statistics
Market cap
$237.84M
EPS (TTM)
-$2.11
52-week range
2.90 – 7.75
Day range
3.78 – 4.00
Volume / Avg
88.48K / 238.88K
Beta
—

52-week range

$2.90$7.75

CAMP stock today

On Nov 20, CAMP ended the session at $3.79, shedding $0.21 (5.25%), versus the S&P 500's 3.70% decline. Trading was light, with 88.48K shares changing hands, about 37% of the average daily volume. Shares are 51.1% below their 52-week high of $7.75, set on Mar 9, 2026 and 30.7% above the 52-week low of $2.90, near the bottom of the past year's range.

CAMP is down 38.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 30.7%. CAMP4 Therapeutics has posted a net loss over the last twelve months (EPS of -$2.11), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About CAMP4 Therapeutics

Company profile

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Joshua Mandel-Brehm
Headquarters
Watertown, MA
Employees
48
IPO year
2024

Financial highlights

Full financials

In fiscal 2025, CAMP4 Therapeutics generated $3.5 million in revenue, up 436.5% from fiscal 2024, its 2nd consecutive year of revenue growth. CAMP4 Therapeutics reported a net loss of $80.4 million, compared with a loss of $51.8 million a year earlier. Operating margin was -1502.4%.

CAMP4 Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue$3.50M$652.00K$350.00K
Growth+436.50%+86.29%—
Net income$-80.40M$-51.79M$-49.29M
EPS (diluted)$-2.65$-11.04$-124.80

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$10.22+169.66%

  • Strong buy 3
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $6.00High $15.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.37 vs $-0.20
Surprise
-85.00%

CAMP news

All CAMP news

CAMP4 Therapeutics peers

Health Care sector
CAMP peer companies
CompanyPrice% ChgMarket capCompare
LFCRLifecore Biomedical Inc.6.39+0.31%$242.22Mvs CAMP
TTRXTurn Therapeutics Inc.8.10-6.31%$247.49Mvs CAMP
QTTBQ32 Bio Inc.8.34-1.65%$249.57Mvs CAMP
ENTAEnanta Pharmaceuticals Inc.7.62-4.51%$222.19Mvs CAMP
IMRXImmuneering Corporation Class A3.38-2.03%$218.90Mvs CAMP
RCKTRocket Pharmaceuticals Inc.1.95-7.58%$217.74Mvs CAMP
KROSKeros Therapeutics Inc.11.08-2.72%$217.44Mvs CAMP
PRLDPrelude Therapeutics Incorporated3.23-0.77%$258.63Mvs CAMP

Indexes, lists and sector

CAMP4 Therapeutics stock FAQ

What is CAMP4 Therapeutics's stock price today?

CAMP last traded at $3.79 as of Nov 20, 4:00 PM EST, down 5.25% on the day. Prices are delayed at least 15 minutes.

Who is CAMP4 Therapeutics's CEO?

Mr. Joshua Mandel-Brehm is the chief executive officer of CAMP4 Therapeutics Corporation, which has about 48 employees.

What is the CAMP 52-week high?

The 52-week high for CAMP is $7.75 and the 52-week low is $2.90. The stock is currently 51.1% below its high.

Compare CAMP